Valeo Chalks Up Another Milestone For Canadian Enoxaparin Biosimilars
Follows Backing To Be Listed On The Quebec Public Health Plan
Executive Summary
Canada’s Valeo Pharma insists it has “worked tirelessly to ensure a robust supply of Redesca,” after completing another milestone for the company’s enoxaparin biosimilar product.
You may also be interested in...
Valeo Pharma To Launch Enoxaparin In Canada Early Next Year
Canadian firm Valeo Pharma is looking to make a splash with enoxaparin biosimilars, Redesca and Redesca HP, following approval from Health Canada.
Coherus Completes $50m Share Offer To Novel Partner Junshi Biosciences
Coherus BioSciences has sold a little under 2.5 million shares to partner Junshi Biosciences, giving the firm additional capital following a large debt financing last year.
Alvogen’s Lotus Bags $50m Investment To Boost Access In Asia
Lotus Pharmaceuticals aims to build a stronghold in Thailand and beyond, after the Alvogen subsidiary announced a partnership with a subsidiary of Thai state-owned conglomerate PTT, which includes a $50m capital injection.